Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen Granule to treat idiopathic membranous nephropathy.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
wanglin
NCT07516964 · Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, and more
NCT04456816 · Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy
NCT04745728 · Idiopathic Membranous Nephropathy
NCT03804359 · Idiopathic Membranous Nephropathy
NCT05850845 · Hyperspectral Imaging, Idiopathic Membranous Nephropathy, and more
Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions